Product Program year 2025 Source: CMS Open Payments

Zyprexa

Drug Neuroscience

NDC 0002-4117-30

Open in the dashboard

General payments

$475

25 payments

Research payments

$0

0 payments

Through program year 2025, $475 in general payments and $0 in research payments were reported against Zyprexa (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2025 General $69 1
2021 General $247 13
2019 General $158 11

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $406 24 payments
  2. Eli Lilly and Company $69 1 payment
Top recipients General payments · program year 2025
  1. Rakesh Jain Psychiatry · Lake Jackson, TX $69 100% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Psychiatry Psychiatry & Neurology $69 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Texas $69 100% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

5,957

Prescriptions dispensed, refills included

Drug cost

$6,702,470

Paid at the pharmacy, in all

Medicare Part D drugs matched to ZYPREXA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Zyprexa Olanzapine Same name 278 4,361 $4,729,045
Zyprexa Zydis Olanzapine Similar name 56 769 $1,112,277
Zyprexa Relprevv Olanzapine Pamoate Similar name 41 827 $861,148

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 195 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Nilanjan Gajare Psychiatry MI 52 $29,480 None on record
Shasta Mitchell Nurse Practitioner UT 49 $53,465 None on record
Afiah Ahsan Psychiatry WV 44 $48,108 None on record
Beth Darling Psychiatry AZ 40 $26,786 None on record
Julana Schenk Psychiatry UT 38 $52,050 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 195 with Patron
25 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record